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Dear Editor,
Influenza affects humans of all ages; however, elderly people
have increased susceptibility to infections and are especially
predisposed to complications.1 A number of global efforts have
increased influenza vaccination administration in elderly people to
reduce complications, particularly when seasonal influenza infec-
tions peak.2 To date, much is known about how influenza infection
and host immunity interact during pathogenesis, which has led to
a number of vaccines.3,4 However, the impact of influenza
vaccines in older people is modest.2 Hence, the underlying
pathophysiological mechanisms responsible for the worsening of
influenza infection in old age are still elusive.
Adiponectin is secreted by adipose tissue; it has insulin-
sensitizing,5 anti-atherogenic,6 and anti-inflammatory properties.7
The hormone binds two main receptors to exert its effects:
adiponectin receptor 1 (Adipor1) and adiponectin receptor 2
(Adipor2).8 Adiponectin signaling through the two different
receptors has been shown to exert unique effects in different
disease states and tissues.8,9 Interestingly, adiponectin levels are
elevated in elderly individuals, showing negative correlations with
several age- and obesity-related metabolic disturbances.10 How-
ever, the role of adiponectin and its signaling during infections in
the elderly population have not been investigated.
Our initial observation was that adiponectin levels were
elevated in bronchoaveolar lavage fluid (BALF) obtained from
old patients with confirmed influenza infection (Fig. 1a). We also
observed mRNA and protein expression of adiponectin in cultured
lung tissue cells from old patients with confirmed influenza
infection that was greater than that of matched and young control
cells (Fig. 1b, c and Supplementary Fig. 1a). Only IL-18 mRNA
expression was increased in aged lung tissue with confirmed
influenza infection compared to age-matched and young control
tissue (Fig. 1d). An increase in adiponectin and IL-18 concentra-
tions in the sera of either young or old patients with or without
influenza infection was not detected (Supplementary Fig. 1b, c).
We next treated isolated human lung cells with recombinant
adiponectin to test whether IL-18 levels were directly correlated
with increased adiponectin levels in lung tissue cells. IL-18 mRNA
expression was elevated after treatment of aged lung tissue cells
with recombinant adiponectin, and it was further increased in
aged lung tissue with influenza infection compared to that of
control cells (Fig. 1e). At this stage, we wanted to investigate
whether a loss or decrease of adiponectin could decrease the
worsening of influenza. Interestingly, we noticed that only aged
Adipoq−/− mice displayed reduced disease outcomes following
influenza infection compared to those of control mice (Fig. 1f, g
and Supplementary Fig. 1c-d). In addition, only Adipoq−/− old
mice with influenza infection showed a decrease in IL-18 mRNA
and protein expression (Supplementary Fig. 1e, f). There was no
change in IL-18 concentrations in the sera of young or old WT and
Adipoq−/− mice (Supplementary Fig. 1g, h). We also established
that neutralizing adiponectin could act as a therapeutic agent that
could attenuate the worsening of influenza infection in old age.
Only old WT mice with influenza infection showed protection and
reduced disease outcomes after anti-adiponectin antibody treat-
ment (Fig. 1h, i and Supplementary Fig. 2a, b). Compared to
control mice, these mice also displayed decreased IL-18 mRNA
(lung tissue; Supplementary Fig. 2c) or protein (BALF; Supplemen-
tary Fig. 2d) expression following influenza infection.
We also investigated which main adiponectin receptor was
responsible for the increase in IL-18 levels during influenza
infection in old age. We observed that only old Adipor1−/− mice
displayed decreased disease outcomes post influenza infection
compared to that of control mice (Supplementary Fig. 3a-d). IL-18
mRNA (lung tissue; Supplementary Fig. 3e) or protein (BALF;
Supplementary Fig. 3f) expression was only decreased in old
Adipor1−/− mice with influenza infection compared to control
mice. In contrast, Adipor2−/− mice did not show any change in
disease outcomes (Supplementary Fig. 4a-d) or IL-18 mRNA (lung
tissue; Supplementary Fig. 4e) or protein (BALF; Supplementary
Fig. 4f) expression following influenza infection compared to that
of control mice. We also treated old WT and IL-18−/− mice with
rAdiponectin to test whether the worsening of influenza infection
in old age caused by adiponectin was IL-18 dependent. We
observed that only IL-18−/− mice with or without rAdiponectin
had increased survival following influenza infection compared to
those of control mice (Supplementary Fig. 5a-d). In addition, old
wild-type mice treated with rAdiponectin showed an increase in
IL-18 mRNA (lung tissue; Supplementary Fig. 5e) or protein (BALF;
Supplementary Fig. 5f) expression following influenza infection
compared to that of control mice. Finally, we observed decreased
protein expression and activity of intercellular proteins involved in
the activation cascade of IL-18 in human lung samples (Supple-
mentary Fig. 6f, g). However, we did not determine a detailed
immune mechanism of why neutralizing adiponectin helps stop
the worsening of influenza infection in elderly individuals, which is
a limitation of our study. Future studies should concentrate on
investigating the response of CD8+ T cells in this context and
other immune mediators, such as interferon stimulated genes.
In summary, our data point to a new detrimental role for the
hormone adiponectin in aged lung tissue during influenza
infection. Adiponectin signaling seems to have no effect on
healthy and infected young models or on old healthy models,
which shows the potential of targeting this novel signaling axis
only in elderly patients during periods of influenza infection. We
also further defined adiponectin signaling in aged mice with
infection and showed that the direct action of the hormone is
dependent on Adiopr1-IL-18 signaling. Adiponectin may prove to
be a new therapeutic target for intervention and reducing the
severity of influenza infections in elderly people.
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Fig. 1 Adiponectin exacerbates influenza infection in old age via IL-18. a Adiponectin concentration in human BALF samples obtained from
young (18–35) or old (60–74) patients with or without influenza (n= 8–13). b Gene and (c) Protein expression of adiponectin from cultured
lung samples obtained from young (18–35 old) or old (60–74 old) patients with or without influenza. d Gene expression of cytokines from
lung biopsies obtained from young (18–35 old) or old (60–74 old) patients with or without influenza (n= 8). e IL-18 mRNA expression in
cultured lung samples obtained from young (18–35 old) or old (60–74 old) patients with or without influenza treated with either the vehicle
control (H2O) or human rAdiponectin (3 μg/ml) for 24 h (n= 3). f H&E staining of the lungs (g) survival rate of influenza-infected (10×MLD50
H1N1 influenza virus) WT or Adipoq−/− young (3 months to 9 months old) and old (20 months to 24 months old) mice (n= 6–12). h H&E
staining of the lungs (i) survival rate of influenza-infected (10×MLD50 H1N1 influenza virus) WT young (3 months to 9 months old) and old
(20 months to 24 months old) mice treated with either the control (IgG1: 50 µg per mouse daily) or with mouse adiponectin antibody (50 µg
per mouse daily) until the final timepoints (n= 6–12). All RT-qPCR gene expression levels were normalized to the endogenous level of 18 s. All
data are expressed as the mean ± S.E.M. of n observations. A Student’s unpaired t test or ANOVA with Tukey’s comparison were used for
statistical analysis. Survival curves were compared using log rank Mantel–Cox curve comparison, and groups were compared to either old
Adipoq−/− mice or old WT mice+ rAdiponectin in their respective graphs. NS= non–significant. p < 0.05, p < 0.01, p < 0.001 or p < 0.0001 are
represented in figures as *, **, *** or ****, respectively
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